Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2020 Ended December 31, 2019 and Provides Conference Call Information

Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals and SunGen Pharma Receive FDA Approval for Generic Adderall XR(R)

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2020 Ended September 30, 2019 and Provides Conference Call Information

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2020 Financial Results on November 13, 2019

Elite Pharmaceuticals Receives FDA Approval for Codeine and Acetaminophen Combo

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2020 Ended June 30, 2019 and Provides Conference Call Information

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2020 Financial Results on August 12, 2019

Elite Pharmaceuticals Announces Commercial Launch of Dantrolene Capsules with Marketing Partner Lannett Company

Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2019 and Provides Conference Call Information

Elite Pharmaceuticals, Inc. Delays Fourth Quarter and Year End 2019 Earnings Release Date and Conference Call

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Year-end Financial Results on June 17, 2019